Last login: Thu Jul  2 08:04:35 on ttys035
harry@Harrys-MacBook-Air ~ % cd ~code/ventureX
zsh: no such user or named directory: code
harry@Harrys-MacBook-Air ~ % cd /Users/harry/code/ventureX        
harry@Harrys-MacBook-Air ventureX % claude


























▗ ▗   ▖ ▖  Claude Code v2.1.204
           Fable 5 with xhigh effort · Claude Team
  ▘▘ ▝▝    ~/code/ventureX
 
 ▎ Extended: Fable 5 is included in your weekly limit
 ▎ Through July 12, you can use up to 50% of your weekly usage limit on Fable 5. If you hit your limit, you can continue on Fable 5 with usage credits. Fable 5 draws down usage faster than Opus 4.8. Run /model and select Fable to use it. Learn more
 ▎ (https://support.claude.com/en/articles/15424964-claude-fable-5-promotional-access)

❯ So, super excited to get started on making some improvements to our codebase. Let me give you some context on what we are building, although a lot of the info you can already see in @claude.md . VentureX is a competitor analysis tool, which takes some information    
  about a real company, including documents and text inputs, and creates a synthetic VentureX which we use to find suitable competitors. We do this because our clients are often large companies that are trying to create new, high value initiatives that could be a new  
  product line, a new company, entering a new market etc. By using the company's name, we found that our results were skewed. For example, if we were working with Samsung on a project where they were trying to create their own version of Starlink (aka run their own    
  sattelite constellation), if we used the word Samsung, we would get a lot of "competitors" such as Apple (because of the phones) or Sony (their electrical products). By creating the synthetic VentureX, we are saying there is a mythical company that has a huge amount 
  of cash and talent behind it, that wants to build sattelites and send them in to orbit to rival SpaceX. By clearing out the word Samsung, and just focussing ona  clear vertical, our results were much better. Right now, we have run a few cases. Currently, our focus   
  is on ABB, which is considering entering the RackPDU market. You can find out more about them in the @test-cases/ folder. In terms of outputs, you can view the final table in @outputs/ . There is both a CSV and an HTML of the output. Two big things have now changed. 
  1) We have a top tier investor who wants to see the results and artifacts. He is not going to go through the process, we are, but he will see the outputs. This means we have to improve the quality of it, both in terms of content and UI. Secodnly, we have got the     
  major unlock, Fable 5. With the worlds best coding agent, we can make this a whole lot better. Step 1 is for you to review the entire codebase, and do your best to understand the task at hand. Once we have that settled, we can start working together on where we      
  think the major problems are, how they can be improved, and what would take this from interesting to wow. We have a bit of time on our hands to make this work, so let's go through this thoroughly so we knock it out of the park. I believe in you                       
  ⎿  Read claude.md (507 lines)
  ⎿  Listed directory test-cases/
  ⎿  Listed directory outputs/

⏺ Great context — thank you. Let me do a thorough review: I'll map the repo structure and recent history first, then read the planning docs and the investor-facing outputs myself while fanning out agents to deep-read the source.
   
  Searched for 1 pattern, ran 1 shell command 
   
⏺ 3 background agents launched (↓ to manage)
   ├ Deep-read pipeline backend
   ├ Deep-read UI layer
   └ Deep-read prompts and evals

  Searched for 1 pattern, read 8 files, ran 4 shell commands 

⏺ Branch state is clean — wednesday is identical to main and fully pushed. Let me look at a few actual CSV data rows to see how the export reads to a human.
                                                                                                                                                                                                                                                                             
⏺ Bash(awk 'NR>=12 && NR<=14' outputs/table.csv | cut -c1-3000)                                                                                                                                                                                                              
  ⎿  nference,c84cf128-8f4e-477a-992f-3d42fdd2387a,,"nference, Inc.",nference,2013,operating,"Cambridge, Massachusetts, USA",private,,"{""as_of"":""2024"",""value"":""300-500""} [inferred]",[unknown] Private company; nference has not publicly disclosed annual revenue  
     figures.,"[{""date"":""2020-08"",""type"":""Series C"",""amount"":""~$60M"",""counterparty"":""Matrix Capital Management, NTTVC, Mayo Clinic""},{""date"":""2022-12"",""type"":""Series D"",""amount"":""~$77M"",""counterparty"":""NTTVC and existing                  
     investors""},{""date"":""2021"",""type"":""Subsidiary spinout"",""amount"":null,""counterparty"":""Anumana (AI-ECG JV with Mayo Clinic)""}] [inferred]","[{""name"":""Murali Aravamudan"",""role"":""Co-Founder & CEO""},{""name"":""Venky                              
     Soundararajan"",""role"":""Co-Founder & Chief Scientific Officer""},{""name"":""Ajit Rajasekharan"",""role"":""Co-Founder &                                                                                                                                             
     CTO""}]","{""ir"":null,""blog"":null,""press"":""https://nference.com/news/"",""careers"":""https://nference.com/careers/"",""pricing"":null,""homepage"":""https://nference.com/""}                                                                                    
     [inferred]",,"{""as_of"":""2022-12"",""value"":""~1000000000"",""currency"":""USD""} [inferred]",[unknown] Cannot confirm a specific material event from the past 12 months with sufficient confidence; private company with intermittent public disclosures.,"nSights  
     is a real-world evidence (RWE) generation platform built on de-identified longitudinal data from 11M+ patient lives sourced from academic medical center partners, serving life-sciences and pharma research use cases. [cite:                                          
     https://v1.nference.com/nsights]",platform [cite: https://www.nference.com/],"Federated AI network with long-term, exclusive-style data partnerships with top-ranked academic medical centers (e.g., Mayo Clinic, Emory), giving nference proprietary access to         
     de-identified longitudinal clinical data computable through its AI tooling. [cite: https://www.businesswire.com/news/home/20231205118996/en/nference-and-Emory-Healthcare-Collaborate-Adding-Another-Top-Ranked-Medical-Center-to-Federated-Data-Network]",B2B-E        
     [inferred] [cite: https://nference.com/news/ZpjxohEAACEAbmNV],Head of R&D / Real-World Evidence at pharma; Chief Research Officer / CMIO at academic medical centers [inferred],"[unknown] M13 citations name marquee customers (Takeda, Mayo Clinic, Emory) but do not 
     disclose revenue concentration figures.",licensing [inferred] [cite: https://www.nference.ai/health-systems],"{""notes"":""No public pricing disclosed for nSights or RWE data licensing; deals appear bespoke (e.g., Takeda strategic                                  
     alliance)."",""range_low"":null,""disclosure"":""opaque"",""range_high"":null} [cite: https://www.nference.com/]","[unknown] No gross margin figures disclosed in supplied citations; Latka revenue figure ($36.7M, 492 employees) is reported but margin not           
     stated.","[""Mayo Clinic (founding data partner)"",""Emory Healthcare (federated data network partner)""] [cite: https://www.businesswire.com/news/home/20231205118996/en/nference-and-Emory-Healthcare-Co                                                              
     GRAIL,0d38c151-7c38-4023-a52e-164accfce0d6,,"GRAIL, Inc.",GRAIL,2016,operating,"Menlo Park, California, USA",public,,"{""as_of"":""FY2024"",""value"":""approximately 1,100""}                                                                                          
     [inferred]","{""fy"":""FY2024"",""value"":125000000,""currency"":""USD"",""source_type"":""reported""} [inferred]","[{""date"":""2017"",""type"":""Series B"",""amount"":""~$900M"",""counterparty"":""ARCH Venture Partners, Johnson & Johnson, Bristol-Myers Squibb,  
     others""},{""date"":""2018"",""type"":""Series C"",""amount"":""~$300M"",""counterparty"":""Multiple investors including Ally Bridge Group""},{""date"":""2020-09"",""type"":""Acquisition agreement"",""amount"":""$8B"",""counterparty"":""Illumina (announced        
     acquisition)""},{""date"":""2021-08"",""type"":""Acquisition closed"",""amount"":""$7.1B"",""counterparty"":""Illumina (closed despite regulatory objections)""},{""date"":""2023-10"",""type"":""Regulatory divestiture                                                
     order"",""amount"":null,""counterparty"":""European Commission / FTC (ordered Illumina to divest GRAIL)""},{""date"":""2024-06"",""type"":""Spin-off"",""amount"":null,""counterparty"":""Illumina (distributed GRAIL shares to Illumina shareholders; GRAIL listed on  
     Nasdaq)""}]","[{""name"":""Bob Ragusa"",""role"":""Chief Executive Officer""},{""name"":""Aaron Freidin"",""role"":""Chief Financial Officer""},{""name"":""Joshua Ofman"",""role"":""President""}]                                                                     
     [inferred]","{""ir"":""https://investors.grail.com"",""blog"":null,""press"":""https://grail.com/press-releases/"", Jump to bottom (ctrl+End) ↓ om/careers/"",""pricing"":null,""homepage"":""https://grail.com""}",NASDAQ:GRAL,[unknown] Public company — market cap   
                                                                                                                                                                                                                                      new task? /clear to save 347.9k tokens
